



LKT Laboratories, Inc.

AZD-7762 Hydrochloride

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID A9912

CAS No. 1246094-78-9

Chemical Name

Synonym AZD-7762 HCl

Formula $C_{17}H_{19}FN_4O_2S \cdot HCl$

Formula Wt. 398.88

Melting Point


Purity $\geq 98\%$

Solubility DMSO 50 mg/mL (137.96 mM)
Water Insoluble
Ethanol Insoluble

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description AZD-7762 is an inhibitor of checkpoint kinase (CHK) 1 that increases sensitivity to DNA-damaging compounds. AZD-7762 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for a variety of cancers. In breast cancer and ovarian cancer cells, AZD-7762 inhibits cellular proliferation. In animal models of breast cancer, AZD-7762 inhibits tumor growth and increases survival rates. This compound displays somewhat limited efficacy due to cardiac toxicity.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
A9912	1 mg	\$97.40
A9912	5 mg	\$168.80
A9912	10 mg	\$265.30

References Bryant C, Rawlinson R, Massey AJ. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. *BMC Cancer*. 2014 Aug 7;14:570. PMID: 25104095.

Sausville E, Lorusso P, Carducci M, et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2014 Mar;73(3):539-49. PMID: 24448638.

Ma CX, Cai S, Li S, et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. *J Clin Invest*. 2012 Apr;122(4):1541-52. Erratum in: *J Clin Invest*. 2012 Jul 2;122(7):2702. PMID: 22446188.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.